Medically reviewed by Jay N. Yepuri, MD Irritable bowel syndrome with constipation (IBS-C) is a type of IBS, a condition that causes different digestive symptoms. The main symptom of IBS-C is ...

Findings showed 30% of patients taking linaclotide 145mcg achieved the primary endpoint of combined responder. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

A study recently published in Gastroenterology presents a possible breakthrough in the treatment of irritable bowel syndrome. According to a June 5 news release, the trial included 238 patients across ...

The Phase 3 ACCEL clinical trial represents important progress in Ardelyx’s goal of expanding the patient population who may benefit from IBSRELA, beyond its lead indication for irritable bowel ...

Approximately 2% of patients with irritable bowel syndrome (IBS) have a mutation of the SCN5A gene that disrupts sodium channel function, according to a genotype analysis published online March 10 in ...

Ardelyx introduced Ibsrela into the well-established IBS-C market and implemented its strategy to attain consistent market. The prolonged absence of effective treatment choices for IBS-C patients ...

A bilayered chenodeoxycholic acid system could relieve colon cramping and improve patient experience, according to a Dec. 8 release from Boston-based Brigham and Women’s Hospital. Citing previous ...

WALTHAM, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

Exocrine pancreatic insufficiency (EPI) and irritable bowel syndrome (IBS) are gastrointestinal (GI) conditions that share certain symptoms, such as abdominal pain, bloating, and changes to bowel ...